US equities |
SPCX $144.75 ▼-9.14% MU $856.49 ▼-6.26% NVDA $212.21 ▼-4.40% META $648.85 ▼-6.98% TSLA $374.58 ▼-3.08% AAPL $348.22 ▲+1.23% AMD $507.93 ▼-8.10% SNDK $1,260.93 ▼-8.51%
FinancialContent

Articles published by Molecular Partners

< Previous 1 2 3 Next >
News headline image
Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners to Hold Three Poster Presentations at AACR 2026
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Reports Highlights and Financial Results for Full Year 2025
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
News headline image
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
< Previous 1 2 3 Next >